oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 2 )

2019 ( 207 )

2018 ( 322 )

2017 ( 297 )

Custom range...

Search Results: 1 - 10 of 297668 matches for " Zain J "
All listed articles are free for downloading (OA Articles)
Page 1 /297668
Display every page Item
Romidepsin in the treatment of cutaneous T-cell lymphoma
Jain S, Zain J
Journal of Blood Medicine , 2011, DOI: http://dx.doi.org/10.2147/JBM.S9649
Abstract: Romidepsin in the treatment of cutaneous T-cell lymphoma Review (3657) Total Article Views Authors: Jain S, Zain J Published Date April 2011 Volume 2011:2 Pages 37 - 47 DOI: http://dx.doi.org/10.2147/JBM.S9649 Salvia Jain, Jasmine Zain NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USA Abstract: The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly variable. Improving the management of this incurable disease with limited toxicity is an active area of research. Romidepsin is a novel, well-tolerated histone deacetylase inhibitor with promising activity against advanced stages of CTCL. In November 2009, it was approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. This review focuses on the activity, pharmacology, and safety of romidepsin for the treatment of CTCL. Keyword: romidepsin, T-cell lymphoma, HDACis, patients Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Jasmine Zain Peripheral T cell lymphoma: clinical utility of romidepsin Readers of this article also read: Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors Deep vein thrombosis: a clinical review Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation Giant leiomyoma of the gastroesophageal junction: technique and results of endoscopic full-thickness resection Emerging treatments for essential thrombocythemia RGD-tagged helical rosette nanotubes aggravate acute lipopolysaccharide-induced lung inflammation Erratum Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension Management of cutaneous T cell lymphoma: new and emerging targets and treatment options
Peripheral T cell lymphoma: clinical utility of romidepsin
Zain J, Sawey K
Blood and Lymphatic Cancer: Targets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/BLCTT.S22585
Abstract: ipheral T cell lymphoma: clinical utility of romidepsin Review (1572) Total Article Views Authors: Zain J, Sawey K Published Date June 2012 Volume 2012:2 Pages 109 - 115 DOI: http://dx.doi.org/10.2147/BLCTT.S22585 Received: 01 March 2012 Accepted: 30 March 2012 Published: 13 June 2012 Jasmine Zain, Kathryn Sawey NYU Langone Medical Center, New York, USA Introduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant tumor cells after exposure to conventional chemotherapy have led researchers to study indirect targets, like the tumor vasculature. A more recent indirect approach involves targeting the epigenetic modifiers, DNA methyltransferase and histone deacetylase. Histone deacetylase inhibitors have been shown to be active cytotoxic agents in T cell lymphoma. The current treatments approved by the US Food and Drug Administration for relapsed cutaneous T cell lymphoma are vorinostat and romidepsin. The diversity and rarity of peripheral T cell lymphomas present a challenge for effective treatment. With their poor overall survival rate, new targeted therapies need to be developed.
Peripheral T cell lymphoma: clinical utility of romidepsin
Zain J,Sawey K
Blood and Lymphatic Cancer: Targets and Therapy , 2012,
Abstract: Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant tumor cells after exposure to conventional chemotherapy have led researchers to study indirect targets, like the tumor vasculature. A more recent indirect approach involves targeting the epigenetic modifiers, DNA methyltransferase and histone deacetylase. Histone deacetylase inhibitors have been shown to be active cytotoxic agents in T cell lymphoma. The current treatments approved by the US Food and Drug Administration for relapsed cutaneous T cell lymphoma are vorinostat and romidepsin. The diversity and rarity of peripheral T cell lymphomas present a challenge for effective treatment. With their poor overall survival rate, new targeted therapies need to be developed.Keywords: peripheral T cell lymphoma, treatment, romidepsin
Romidepsin in the treatment of cutaneous T-cell lymphoma
Jain S,Zain J
Journal of Blood Medicine , 2011,
Abstract: Salvia Jain, Jasmine ZainNYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USAAbstract: The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly variable. Improving the management of this incurable disease with limited toxicity is an active area of research. Romidepsin is a novel, well-tolerated histone deacetylase inhibitor with promising activity against advanced stages of CTCL. In November 2009, it was approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. This review focuses on the activity, pharmacology, and safety of romidepsin for the treatment of CTCL.Keyword: romidepsin, T-cell lymphoma, HDACis, patients
Synchronous Bilateral Lumbotomy in a Child with Bilateral Stone Disease and Renal Failure: An Old Operation Re-visited
Ward J,Zakaria M,Al Shareef Zain
Saudi Journal of Kidney Diseases and Transplantation , 1999,
Abstract:
Serum Matrix Metalloproteinase 3 and Tissue Inhibitor Metalloproteinase 1 in Vascular Dementia: A Comparative Study  [PDF]
Mohammed Zain Abdelwadoud Hussein
Advances in Aging Research (AAR) , 2015, DOI: 10.4236/aar.2015.45016
Abstract: Aim: To compare serum level of matrix metalloproteinase 3 (MMP3) and tissue inhibitor metallo-proteinase 1 (TIMP1) in vascular dementia patients and healthy control subjects. Methods: A case control study was carried out in Ain Shams University hospital, Cairo, Egypt. 32 cases with vascular dementia were collected and classified into 2 subgroups; vascular dementia of multiinfarct type (VDMI) 14 patients, and vascular dementia of subcortical type (VDSC) 18 subjects. 23 cases with normal cognitive functions were collected as control group. Cases were subjected to comprehensive geriatric assessment, neurological examination, neuropsychological testing and brain CT scan. Blood sample was collected to analyze serum level of matrix metalloproteinase 3 (MMP3) and tissue inhibitor metalloproteinase 1 (TIMP1). Results: Mean serum level of TIMP1 (20.85 × 103 picogram/ml) was significantly lower than mean serum level of TIMP1 in control group (27.69 × 103 picogram/ml) (p = 0.018). The same finding was also evident when comparing VDMI subgroup mean serum TIMP1 (18.71 × 103 pc/ml) to control group (p = 0.025). There was no significant difference between mean serum MMP3 levels in cases group (mean = 67.39 × 103) as compared to control group (mean = 61.65 × 103 pc/ml) (p = 0.519). Conclusion: Patients with VD particularly VDMI has lower serum level of TIMP1 as compared to control group.
A Survey of Software Packages Used for Rough Set Analysis  [PDF]
Zain Abbas, Aqil Burney
Journal of Computer and Communications (JCC) , 2016, DOI: 10.4236/jcc.2016.49002
Abstract: Soft computing is a combination of methods that complement each other when dealing with ambiguous real life decision systems. Rough Set Theory (RST) is a technique used in soft computing that enhances the idea of classical sets to deal with incomplete knowledge and provides a mechanism for concept approximation. It uses reducts to isolate key attributes affecting outcomes in decision systems. The paper summarizes two algorithms for reduct calculation. Moreover, to automate the application of RST, different software packages are available. The paper provides a survey of packages that are most frequently used to perform data analysis based on Rough Sets. For benefit of researchers, a comparison of based on functionalities of those software is also provided.
Successful management of aggressive fibromatosis of the neck using wide surgical excision: a case report
Zain A Sobani, Montasir Junaid, Mumtaz J Khan
Journal of Medical Case Reports , 2011, DOI: 10.1186/1752-1947-5-244
Abstract: We report the case of a 39-year-old Pakistani man who presented with a two-month history of a lump on the right side of his neck. The mass was excised and histopathological analysis revealed a case of aggressive fibromatosis.Due to the rarity of the condition no guidelines are available on the indications and extent of each modality. Due to its aggressive behavior and tendency to invade local structures and recur, a multi-modality management strategy is usually employed. On the basis of this case, we suggest that aggressive surgery is a viable management option and may be successfully used as a single modality treatment.Aggressive fibromatosis (AF) is a benign tumor, thought to arise from deep musculoaponeurotic structures [1], characterized by local invasion and recurrence that can occur anywhere in the body. It has rarely been reported in the head and neck region, with 179 cases documented between 1968 and 2008.Due to the tendency of AF to invade local structures and recur, a multi-modality management strategy is usually employed. However due to its rarity in the head and neck, no guidelines are available on the indications and extent of each modality. Here we report a case of AF of the neck successfully managed by wide surgical excision; with no signs of recurrence 22 months after surgery.A 39-year-old Pakistani man had presented to our General Surgery clinic with a two-month history of a lump on the right side of his neck. There were no associated symptoms. There was no history of tobacco or irritant use. On physical examination a fixed mass, 4 cm in size, was palpated in right level III. It was not associated with any changes in the overlying skin. An examination of his upper aerodigestive tract was unremarkable. The mass was excised by a general surgeon. Histopathological analysis demonstrated spindle-shaped cells with no identifiable nuclear pleomorphism or mitotic activity. The cells stained positive for anti-smooth muscle actin (ASMA), favoring a smooth mus
Tibial shaft fractures in football players
Winston R Chang, Zain Kapasi, Susan Daisley, William J Leach
Journal of Orthopaedic Surgery and Research , 2007, DOI: 10.1186/1749-799x-2-11
Abstract: A retrospective study of all tibial football fractures that presented to a teaching hospital was undertaken over a 5 year period from 1997 to 2001. There were 244 tibial fractures treated. 24 (9.8%) of these were football related. All patients were male with a mean age of 23 years (range 15 to 29) and shin guards were worn in 95.8% of cases. 11/24 (45.8%) were treated conservatively, 11/24 (45.8%) by Grosse Kemp intramedullary nail and 2/24 (8.3%) with plating. A difference in union times was noted, conservative 19 weeks compared to operative group 23.9 weeks (p < 0.05). Return to activity was also different in the two groups, conservative 27.6 weeks versus operative 23.3 weeks (p < 0.05). The most common fracture pattern was AO Type 42A3 in 14/24 (58.3%). A high number 19/24 (79.2%) were simple transverse or short oblique fractures. There was a low non-union rate 1/24 (4.2%) and absence of any open injury in our series.Our series compared similarly with the few reports available in the literature. However, a striking finding noted by the authors was a drop in the incidence of tibial shaft football fractures. It is likely that this is a reflection of recent compulsory FIFA regulations on shinguards as well as improvements in the design over the past decade since its introduction.Football is officially the most popular sport in the world. The Fédération Internationale de Football Association (FIFA) estimates that there are 250 million licensed players in 204 countries with 1% participation at professional level [1]. In the UK, it is estimated that about 10% of the adult population play football at least once a year [2]. It is therefore of considerable importance to the social fabric of society especially in Glasgow where there are two derby teams. Despite this, there are very few good papers in the literature on the epidemiology of tibial shaft fractures in this sporting group [3,4]. In addition, there are conflicting views in the literature. One study described foot
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
Jain S, Diefenbach C, Zain J, O'Connor OA
Core Evidence , 2011, DOI: http://dx.doi.org/10.2147/CE.S13838
Abstract: ging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma Review (6247) Total Article Views Authors: Jain S, Diefenbach C, Zain J, O'Connor OA Published Date April 2011 Volume 2011:6 Pages 43 - 57 DOI: http://dx.doi.org/10.2147/CE.S13838 Salvia Jain, Catherine Diefenbach, Jasmine Zain, Owen A O’Connor NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USA Abstract: Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are refractory to bortezomib and immunomodulatory agents. This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-na ve and bortezomib-exposed populations.
Page 1 /297668
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.